These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35388168)

  • 21. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
    Anantram A; Kundaikar H; Degani M; Prabhu A
    J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL-W makes only minor contributions to MYC-driven lymphoma development.
    Diepstraten ST; La Marca JE; Chang C; Young S; Strasser A; Kelly GL
    Oncogene; 2023 Sep; 42(37):2776-2781. PubMed ID: 37567974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
    Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
    Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
    Willimott S; Baou M; Naresh K; Wagner SD
    Br J Haematol; 2007 Sep; 138(6):721-32. PubMed ID: 17760804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL-2 family isoforms in apoptosis and cancer.
    Warren CFA; Wong-Brown MW; Bowden NA
    Cell Death Dis; 2019 Feb; 10(3):177. PubMed ID: 30792387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
    Lee EF; Harris TJ; Tran S; Evangelista M; Arulananda S; John T; Ramnac C; Hobbs C; Zhu H; Gunasingh G; Segal D; Behren A; Cebon J; Dobrovic A; Mariadason JM; Strasser A; Rohrbeck L; Haass NK; Herold MJ; Fairlie WD
    Cell Death Dis; 2019 Apr; 10(5):342. PubMed ID: 31019203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.
    Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G
    Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.
    D'Aguanno S; Del Bufalo D
    Cells; 2020 May; 9(5):. PubMed ID: 32455818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCL-2 protein family: attractive targets for cancer therapy.
    Kaloni D; Diepstraten ST; Strasser A; Kelly GL
    Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes.
    Pemberton JM; Nguyen D; Osterlund EJ; Schormann W; Pogmore JP; Hirmiz N; Leber B; Andrews DW
    Elife; 2023 Apr; 12():. PubMed ID: 37078707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.